AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Innovation Article
PDF (1.1 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Advances and prospects of drug clinical research in colorectal cancer in 2022

Dan Su1,2, Chao Liu1,2, Jie Cui1, Jiebing Tang1,2, Yuli Ruan1, Yanqiao Zhang1,2 ( )
Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province China
Clinical Research Center for Colorectal Cancer in Heilongjiang, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province China

Dan Su and Chao Liu contributed equally to this work and shared the first authorship.

Show Author Information

Abstract

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer death worldwide. Clinical research results have provided more treatment opportunities for CRC patients, showing that an optimal combination of existing drugs and new drugs is needed to mitigate the burden of this disease. In this review, we have summarized recent advances in drug clinical research for CRC in 2022, including chemotherapy, targeted therapy, and immunotherapy, to find opportunities for substantial improvements in drug discovery and clinical development methods.

Keywords

immunotherapychemotherapytargeted therapycolorectal cancer

References

1

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1): 7–30. https://doi.org/10.3322/caac.21590
Crossref Google Scholar
2

Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. J Am Med Assoc. 2021;325(7): 669–85. https://doi.org/10.1001/jama.2021.0106
Crossref Google Scholar
3

Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Center. 2022;2(1): 1–9. https://doi.org/10.1016/j.jncc.2022.02.002
Crossref Google Scholar
4

Cremolini C, Rossini D, Lonardi S, Antoniotti C, Pietrantonio F, Marmorino F, et al. Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild‐type metastatic colorectal cancer (mCRC): results of the phase Ⅲ randomized TRIPLETE study by GONO. J Clin Oncol. 2022;40(17_Suppl): LBA3505. https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA3505
Crossref Google Scholar
5

Bond MJG, Bolhuis K, Loosveld OJL, Droogendijk HJ, de Groot JWB, Hendriks MP, et al. LBA21 FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left‐sided and RAS/BRAFV600E wild‐type tumour: phase Ⅲ CAIRO5 study of the Dutch Colorectal Cancer Group. Ann Oncol. 2022;33(7_Suppl): S1389. https://doi.org/10.1016/j.annonc.2022.08.017
Crossref Google Scholar
6

Pinto C, Orlandi A, Normanno N, Maiello E, Calegari MA, Antonuzzo L, et al. LBA22 phase Ⅲ study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first‐line therapy of RAS and BRAF wild‐type (wt) metastatic colorectal cancer (mCRC) patients: the ERMES study. Ann Oncol. 2022;33(7_Suppl): S1390. https://doi.org/10.1016/j.annonc.2022.08.018
Crossref Google Scholar
7

Avallone A, Giuliani F, Nasti G, Montesarchio V, Santabarbara G, Leo S, et al. Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first‐line treatment of patients (pts) with RAS/BRAF wild‐type (wt) metastatic colorectal cancer (mCRC): the IMPROVE study. J Clin Oncol. 2022;40(16_Suppl): 3503. https://doi.org/10.1200/JCO.2022.40.16_suppl.3503
Crossref Google Scholar
8

Chibaudel B, Dourthe L‐M, Andre T, Henriques J, Bourgeois V, Etienne P‐L, et al. STRATEGIC‐1: multi‐line therapy trial in unresectable wild‐type KRAS/NRAS/BRAF metastatic colorectal cancer—a GERCOR‐PRODIGE randomized open‐label phase Ⅲ study. J Clin Oncol. 2022;40(16_Suppl): 3504. https://doi.org/10.1200/JCO.2022.40.16_suppl.3504
Crossref Google Scholar
9

Tabernero J, Yoshino T, Kim TW, Yaeger R, Desai J, Wasan HS, et al. LBA26 BREAKWATER safety lead‐in (SLI): encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC). Ann Oncol. 2022;33(7_Suppl): S1392–3. https://doi.org/10.1016/j.annonc.2022.08.022
Crossref Google Scholar
10

Morris VK, Parseghian CM, Escano M, Johnson B, Raghav KPS, Dasari A, et al. Phase Ⅰ/Ⅱ trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. J Clin Oncol. 2022;40(4_Suppl): 12. https://doi.org/10.1200/JCO.2022.40.4_suppl.012
Crossref Google Scholar
11

Kopetz S, Bekaii‐Saab TS, Yoshino T, Chung C‐H, Zhang X, Tabernero J. SEAMARK: randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first‐line treatment of BRAF V600E‐mutant and microsatellite instability‐high (MSI‐H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC). J Clin Oncol. 2022;40(16_Suppl): TPS3634. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS3634
Crossref Google Scholar
12

Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, et al. Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation (CodeBreaK100): a prespecified analysis of a single‐arm, phase 2 trial. Lancet Oncol. 2022;23(1): 115–24. https://doi.org/10.1016/S1470-2045(21)00605-7
Crossref Google Scholar
13

Klempner SJ, Weiss J, Pelster M, Spira A, Barve M, Ou SHI, et al. LBA24 KRYSTAL‐1: updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation. Ann Oncol. 2022;33(7_Suppl): S1391. https://doi.org/10.1016/j.annonc.2022.08.020
Crossref Google Scholar
14

Sartore‐Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual‐targeted therapy with trastuzumab and lapatinib in treatment‐refractory, KRAS codon 12/13 wild‐type, HER2‐positive metastatic colorectal cancer (HERACLES): a proof‐of‐concept, multicentre, open‐label, phase 2 trial. Lancet Oncol. 2016;17(6): 738–46. https://doi.org/10.1016/S1470-2045(16)00150-9
Crossref Google Scholar
15

Strickler J, Cercek A, Siena S, André T, Ng K, Van Cutsem E, et al. LBA‐2 primary analysis of MOUNTAINEER: a phase 2 study of tucatinib and trastuzumab for HER2‐positive mCRC. Ann Oncol. 2022;33(4_Suppl): S375–6. https://doi.org/10.1016/j.annonc.2022.04.440
Crossref Google Scholar
16

Chalabi M, Verschoor YL, van den Berg J, Sikorska K, Beets G, Lent AV, et al. LBA7 neoadjuvant immune checkpoint inhibition in locally advanced MMR‐deficient colon cancer: the NICHE‐2 study. Ann Oncol. 2022;33(7_Suppl): S1389. https://doi.org/10.1016/j.annonc.2022.08.016
Crossref Google Scholar
17

Shiu K‐K, Andre T, Kim TW, Jensen BV, Jensen LH, Punt CJA, et al. KEYNOTE‐177: phase Ⅲ randomized study of pembrolizumab versus chemotherapy for microsatellite instability‐high advanced colorectal cancer. J Clin Oncol. 2021;39(3_Suppl): 6. https://doi.org/10.1200/JCO.2021.39.3_suppl.6
Crossref Google Scholar
18

Taieb J, Bouche O, André T, Barbier E, Laurent‐Puig P, Bez J, et al. LBA23 avelumab versus standard second‐line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): the SAMCO‐PRODIGE 54 randomised phase Ⅱ trial. Ann Oncol. 2022;33(7_Suppl): S1390–1. https://doi.org/10.1016/j.annonc.2022.08.019
Crossref Google Scholar
19

Overman MJ, Lenz H‐J, Andre T, Aglietta M, Wong MK, Luppi G, et al. Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability‐high/mismatch repair‐deficient (MSI‐H/dMMR) metastatic colorectal cancer (mCRC): five‐year follow‐up from CheckMate 142. J Clin Oncol. 2022;40(16_Suppl): 3510. https://doi.org/10.1200/JCO.2022.40.16_suppl.3510
Crossref Google Scholar
20

Garrido G, Rabasa A, Sánchez B, López MV, Blanco R, López A, et al. Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J Immunol. 2011;187(10): 4954–66. https://doi.org/10.4049/jimmunol.1003477
Crossref Google Scholar
21

Giannis D, Sideris G, Kakos CD, Katsaros I, Ziogas IA. The role of liver transplantation for colorectal liver metastases: a systematic review and pooled analysis. Transplant Rev. 2020;34(4): 100570. https://doi.org/10.1016/j.trre.2020.100570
Crossref Google Scholar
22

Lintoiu‐Ursut B, Tulin A, Constantinoiu S. Recurrence after hepatic resection in colorectal cancer liver metastasis ‐review article. J Med Life. 2015;8(Spec Issue): 12–4. https://doi.org/10.1016/j.annonc.2022.08.022
Crossref Google Scholar
23

Tang W, Ren L, Liu T, Ye Q, Wei Y, He G, et al. Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first‐line treatment for RAS mutant unresectable colorectal liver‐limited metastases: the BECOME randomized controlled trial. J Clin Oncol. 2020;38(27): 3175–84. https://doi.org/10.1200/JCO.20.00174
Crossref Google Scholar
24

Yao Z, Yaeger R, Rodrik‐Outmezguine VS, Tao A, Torres NM, Chang MT, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017;548(7666): 234–8. https://doi.org/10.1038/nature23291
Crossref Google Scholar
25

Hu H, Wang K, Huang M, Kang L, Wang W, Wang H, et al. Modified FOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS/BRAF wild‐type unresectable liver metastases colorectal cancer: the FOCULM multicenter phase Ⅱ trial. Oncologist. 2021;26(1): e90–8. https://doi.org/10.1634/theoncologist.2020-0563
Crossref Google Scholar
26

Xu RH, Shen L, Li J, Xu JM, Bi F, Ba Y, et al. Expert consensus on maintenance treatment for metastatic colorectal cancer in China. Chin J Cancer. 2016;35:13. https://doi.org/10.1186/s40880-015-0067-x
Crossref Google Scholar
27

Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop‐and‐go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol. 2006;24(3): 394–400. https://doi.org/10.1200/JCO.2005.03.0106
Crossref Google Scholar
28

Chibaudel B, Maindrault‐Goebel F, Lledo G, Mineur L, André T, Bennamoun M, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009;27(34): 5727–33. https://doi.org/10.1200/JCO.2009.23.4344
Crossref Google Scholar
29

Waddell T, Gollins S, Soe W, Valle J, Allen J, Bentley D, et al. Phase Ⅱ study of short‐course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. Cancer Chemother Pharmacol. 2011;67(5): 1111–7. https://doi.org/10.1007/s00280-010-1322-0
Crossref Google Scholar
30

Li Y, Li J, Lu M, Wang X, Shen L. Capecitabine maintenance therapy after first‐line chemotherapy in patients with metastatic colorectal cancer. Chin J Cancer Res. 2010;22(3): 181–85. https://doi.org/10.1007/s11670-010-0181-x
Crossref Google Scholar
31

Masuishi T, Kuboki Y, Fakih MG, Strickler JH, Furqan M, Kim EJ, et al. 444TiP trial in progress: a phase Ib study of sotorasib, a selective KRAS G12C inhibitor, in combination with panitumumab and FOLFIRI in treatment naïve and previously treated metastatic colorectal cancer (CodeBreaK 101). Ann Oncol. 2022;33(7_Suppl): S737–8. https://doi.org/10.1016/j.annonc.2022.07.1865
Crossref Google Scholar
32

Clarke CN, Kopetz ES. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J Gastrointest Oncol. 2015;6(6): 660–7. https://doi.org/10.3978/j.issn.2078-6891.2015.077
Crossref Google Scholar
33

Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E‐mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON Study. J Clin Oncol. 2021;39(4): 273–84. https://doi.org/10.1200/JCO.20.02088
Crossref Google Scholar
34

Barras D, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C, et al. BRAF V600E mutant colorectal cancer subtypes based on gene expression. Clin Cancer Res. 2017;23(1): 104–15. https://doi.org/10.1158/1078-0432.CCR-16-0140
Crossref Google Scholar
35

Zhu G, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer. 2021;20(1): 143. https://doi.org/10.1186/s12943-021-01441-4
Crossref Google Scholar
36

Loong HHF, Du N, Cheng C, Lin H, Guo J, Lin G, et al. KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples. Transl Lung Cancer Res. 2020;9(5): 1759–69. https://doi.org/10.21037/tlcr-20-455
Crossref Google Scholar
37

Kuboki Y, Yaeger R, Fakih M, Strickler JH, Masuishi T, Kim EJH, et al. 45MO sotorasib in combination with panitumumab in refractory KRAS G12C‐mutated colorectal cancer: safety and efficacy for phase Ib full expansion cohort. Ann Oncol. 2022;33(9_Suppl): S1445–6. https://doi.org/10.1016/j.annonc.2022.10.077
Crossref Google Scholar
38

Paez D, Meriggi F, Cremolini C, Folprecht G, Korantzis I, Chan E, et al. 437TiP trial in progress: a phase Ⅲ global study of sotorasib, a specific KRAS G12C inhibitor, in combination with panitumumab versus investigator's choice in chemorefractory metastatic colorectal cancer (CodeBreaK 300). Ann Oncol. 2022;33(7_Suppl): S734. https://doi.org/10.1016/j.annonc.2022.07.575
Crossref Google Scholar
39

Meric‐Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, et al. Pertuzumab plus trastuzumab for HER2‐amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open‐label, phase 2a, multiple basket study. Lancet Oncol. 2019;20(4): 518–30. https://doi.org/10.1016/S1470-2045(18)30904-5
Crossref Google Scholar
40

Nakamura Y, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, et al. Circulating tumor DNA‐guided treatment with pertuzumab plus trastuzumab for HER2‐amplified metastatic colorectal cancer: a phase 2 trial. Nat Med. 2021;27(11): 1899–1903. https://doi.org/10.1038/s41591-021-01553-w
Crossref Google Scholar
41

Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, et al. LBA27 additional analyses of MOUNTAINEER: a phase Ⅱ study of tucatinib and trastuzumab for HER2‐positive mCRC. Ann Oncol. 2022;33(7_Suppl): S1394. https://doi.org/10.1016/j.annonc.2022.08.023
Crossref Google Scholar
42

Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, et al. Trastuzumab deruxtecan (DS‐8201) in patients with HER2‐expressing metastatic colorectal cancer (DESTINY‐CRC01): a multicentre, open‐label, phase 2 trial. Lancet Oncol. 2021;22(6): 779–89. https://doi.org/10.1016/S1470-2045(21)00086-3
Crossref Google Scholar
43

Li Q, Liu T, Cui YH, Xu XJ, Xu B, Wang Y, et al. 450P efficacy and safety of pyrotinib‐based therapy in HER2‐positive metastatic colorectal and gastric cancer: a retrospective study. Ann Oncol. 2021;32(5_Suppl): S558. https://doi.org/10.1016/j.annonc.2021.08.971
Crossref Google Scholar
44

Chang J, Xu M, Wang C, Huang D, Zhang Z, Chen Z, et al. Dual HER2 targeted therapy with pyrotinib and trastuzumab in refractory HER2 positive metastatic colorectal cancer: a result from HER2‐FUSCC‐G Study. Clin Colorectal Cancer. 2022;21(4): 347–53. https://doi.org/10.1016/j.clcc.2022.07.003
Crossref Google Scholar
45

Tabernero J, Shen L, Elimova E, Ku G, Liu T, Shitara K, et al. HERIZON‐GEA‐01: zanidatamab + chemo ± tislelizumab for 1L treatment of HER2‐positive gastroesophageal adenocarcinoma. Future Oncol. 2022;18(29): 3255–66. https://doi.org/10.2217/fon-2022-0595
Crossref Google Scholar
46

Lew ED, Oh J, Congdon T, Zhang J, Shoemaker RF. Abstract 2672: ERAS‐007 is a selective ERK1/2 inhibitor with preclinical activity across RAS/MAPK pathway‐driven CRC models. Cancer Res. 2022;82(12_Suppl): 2672. https://doi.org/10.1158/1538-7445.AM2022-2672
Crossref Google Scholar
47

O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell‐based immunotherapy. Nat Rev Clin Oncol. 2019;16(3): 151–67. https://doi.org/10.1038/s41571-018-0142-8
Crossref Google Scholar
48

Diaz LA Jr., Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, et al. Pembrolizumab versus chemotherapy for microsatellite instability‐high or mismatch repair‐deficient metastatic colorectal cancer (KEYNOTE‐177): final analysis of a randomised, open‐label, phase 3 study. Lancet Oncol. 2022;23(5): 659–70. https://doi.org/10.1016/S1470-2045(22)00197-8
Crossref Google Scholar
49

Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, Jensen BV, et al. Health‐related quality of life in patients with microsatellite instability‐high or mismatch repair deficient metastatic colorectal cancer treated with first‐line pembrolizumab versus chemotherapy (KEYNOTE‐177): an open‐label, randomised, phase 3 trial. Lancet Oncol. 2021;22(5): 665–77. https://doi.org/10.1016/S1470-2045(21)00064-4
Crossref Google Scholar
50

Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, et al. Phase Ⅱ open‐label study of pembrolizumab in treatment‐refractory, microsatellite instability‐high/mismatch repair‐deficient metastatic colorectal cancer: KEYNOTE‐164. J Clin Oncol. 2020;38(1): 11–9. https://doi.org/10.1200/JCO.19.02107
Crossref Google Scholar
51

Rocha Lima CMSP, Yothers G, Jacobs SA, Sanoff HK, Cohen DJ, Guthrie KA, et al. Colorectal cancer metastatic dMMR immuno‐therapy (COMMIT) study: a randomized phase Ⅲ study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first‐line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI‐H) metastatic colorectal cancer (mCRC)—NRG‐GI004/SWOG‐S1610. J Clin Oncol. 2022;40(16_Suppl): TPS3647. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS3647
Crossref Google Scholar
52

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD‐1 blockade in tumors with mismatch‐repair deficiency. N Engl J Med. 2015;372(26): 2509–20. https://doi.org/10.1056/NEJMoa1500596
Crossref Google Scholar
53

O'Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez‐Roca C, et al. Safety and antitumor activity of the anti‐PD‐1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS One. 2017;12(12): e0189848. https://doi.org/10.1371/journal.pone.0189848
Crossref Google Scholar
54

Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open‐label, phase 3, randomised, controlled trial. Lancet Oncol. 2019;20(6): 849–61. https://doi.org/10.1016/S1470-2045(19)30027-0
Crossref Google Scholar
55

Lee MS, Loehrer PJ, Imanirad I, Cohen S, Ciombor KK, Moore DT, et al. Phase Ⅱ study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild‐type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Clin Oncol. 2021;39(3_Suppl): 7. https://doi.org/10.1200/JCO.2021.39.3_suppl.7
Crossref Google Scholar
56

Chen EX, Jonker DJ, Loree JM, Kennecke HF, Berry SR, Couture F, et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO.26 Study. JAMA Oncol. 2020;6(6): 831–8. https://doi.org/10.1001/jamaoncol.2020.0910
Crossref Google Scholar
57

Valero C, Lee M, Hoen D, Zehir A, Berger MF, Seshan VE, et al. Response rates to anti‐PD‐1 immunotherapy in microsatellite‐stable solid tumors with 10 or more mutations per megabase. JAMA Oncol. 2021;7(5): 739–43. https://doi.org/10.1001/jamaoncol.2020.7684
Crossref Google Scholar
58

Bullock A, Grossman J, Fakih M, Lenz H, Gordon M, Margolin K, et al. LBA O‐9 botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti‐PD‐1) for metastatic heavily pretreated microsatellite stable colorectal cancer. Ann Oncol. 2022;33:S376. https://doi.org/10.1016/j.annonc.2022.04.453
Crossref Google Scholar
59

Anderson AC, Joller N, Kuchroo VK. Lag‐3, Tim‐3, and TIGIT: co‐inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5): 989–1004. https://doi.org/10.1016/j.immuni.2016.05.001
Crossref Google Scholar
60

Wang M, Du Q, Jin J, Wei Y, Lu Y, Li Q. LAG3 and its emerging role in cancer immunotherapy. Clin Transl Med. 2021;11(3): e365. https://doi.org/10.1002/ctm2.365
Crossref Google Scholar
61

Chocarro L, Blanco E, Zuazo M, Arasanz H, Bocanegra A, Fernández‐Rubio L, et al. Understanding LAG‐3 signaling. Int J Mol Sci. 2021;22(10): 5282. https://doi.org/10.3390/ijms22105282
Crossref Google Scholar
62

Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3—potential mechanisms of action. Nat Rev Immunol. 2015;15(1): 45–56. https://doi.org/10.1038/nri3790
Crossref Google Scholar
63

Gomez‐Roca C, Yanez E, Im S‐A, Castanon Alvarez E, Senellart H, Doherty M, et al. LEAP‐005: a phase Ⅱ multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—results from the colorectal cancer cohort. J Clin Oncol. 2021;39(3_Suppl): 94. https://doi.org/10.1200/JCO.2021.39.3_suppl.94
Crossref Google Scholar
64

Morano F, Raimondi A, Pagani F, Lonardi S, Salvatore L, Cremolini C, et al. Temozolomide followed by combination with low‐sose ipilimumab and nivolumab in patients with microsatellite‐stable, O(6)‐methylguanine‐DNA methyltransferase‐silenced metastatic colorectal cancer: the MAYA Trial. J Clin Oncol. 2022;40(14): 1562–73. https://doi.org/10.1200/JCO.21.02583
Crossref Google Scholar
65

Ree AH, Hamre H, Kersten C, Hofsli E, Guren MG, Sorbye H, et al. Repeat sequential oxaliplatin‐based chemotherapy (FLOX) and nivolumab versus FLOX alone as first‐line treatment of microsatellite‐stable (MSS) metastatic colorectal cancer (mCRC): initial results from the randomized METIMMOX study. J Clin Oncol. 2021;39(15_Suppl): 3556. https://doi.org/10.1200/JCO.2021.39.15_suppl.3556
Crossref Google Scholar
66

Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin‐Babau J, Cohen R, et al. 433P durvalumab and tremelimumab in combination with FOLFOX in patients with previously untreated RAS‐mutated metastatic colorectal cancer: first results of efficacy at one year for phase Ⅱ MEDITREME trial. Ann Oncol. 2021;32(5_Suppl): S551. https://doi.org/10.1016/j.annonc.2021.08.954
Crossref Google Scholar
67

Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open‐label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022;23(7): 876–87. https://doi.org/10.1016/S1470-2045(22)00274-1
Crossref Google Scholar
68

Punt CJA, Bond MJG, Bolhuis K, Loosveld O, Helgason HH, de Groot JW, et al. FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right‐sided and/or RAS/BRAFV600E‐mutated primary tumor: phase Ⅲ CAIRO5 study of the Dutch colorectal cancer group. J Clin Oncol. 2022;40(17_Suppl): LBA3506. https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA3506
Crossref Google Scholar
Cancer Innovation
Volume 2 Issue 2,
April 2023
Pages 99-113
DOI: 10.1002/cai2.62
Cite this article:
Su D, Liu C, Cui J, et al. Advances and prospects of drug clinical research in colorectal cancer in 2022. Cancer Innovation, 2023, 2(2): 99-113. https://doi.org/10.1002/cai2.62

624

Views

43

Downloads

2

Crossref

2

Scopus

Altmetrics
Received: 26 December 2022
Accepted: 15 February 2023
Published: 05 March 2023
© 2023 The Authors.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Return